Viewing nowCombinationJanumax MXR Controlled-Release Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samik Pharmaceutical Co., Ltd.

MFDS item code 202202079 · Approved 2022.05.17 · Insurance code 644004640
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes in managing their blood sugar levels in conjunction with dietary and exercise therapies. It contains both sitagliptin and metformin, which are effective in managing blood sugar and helping to stabilize blood glucose levels. Taking this medication may improve blood sugar control and help prevent complications related to diabetes. Patients are encouraged to maintain consistent dietary control and exercise alongside taking the medication. This medication effectively improves blood sugar management in type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with meals once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, Contraindications, in Precautions for Use). 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg plus their current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine, 50/1000 mg extended-release, once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, General Precautions, in Precautions for Use). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Contraindications, in Precautions for Use).
This medication is used for the treatment of diabetes and contains two active ingredients, sitagliptin and metformin. When taking this medication, there is a possibility of hypersensitivity reactions; if symptoms such as allergic reactions, skin rashes, or difficulty breathing occur, discontinue use immediately and consult a doctor. There is a risk of serious inflammation of the pancreas, known as acute pancreatitis, so if abdominal pain, vomiting, or severe abdominal pain occur, you should visit a hospital immediately. Patients with poor kidney function or those experiencing severe infections or dehydration should not take this medication. Additionally, if you are receiving iodinated contrast agents for radiographic examinations, this medication should be suspended for a period around the examination, and you should resume taking it only after confirming normal kidney function. Women who are pregnant or breastfeeding, as well as children under 18 years of age, should not use this medication as a precaution. During the course of this medication, be cautious of symptoms of hypoglycemia, especially when taken with other hypoglycemic agents or insulin, as the risk of hypoglycemia may increase. The metformin component can rarely cause severe metabolic disturbances known as lactic acidosis, so it should be discontinued in cases of severe dehydration, acute illness, or liver dysfunction. It is important to regularly monitor kidney function, blood tests, and vitamin B12 levels for any abnormalities. If you consume alcohol excessively, the risk of lactic acidosis may increase, so it is advisable to avoid drinking. In case of surgery, this medication should be discontinued 48 hours prior to the surgery, and resuming treatment should only occur after confirming normal kidney function post-surgery. Elderly patients may require dose adjustments based on kidney function, and regular monitoring of kidney function is recommended. If you experience any unusual symptoms or discomfort while taking this medication, consult medical personnel immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius.
A bright blue, bilaterally convex, oval-shaped controlled-release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samik Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.